Oramed gets patent for oral administration of proteins
The United States Patent and Trademark Office has approved Oramed Pharmaceuticals’ (NASDAQ: ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” In a...
View ArticleMedifocus receives U.S. patent for heat activated treatment
Medifocus (OTCQX:MDFZF; TSX-V:MFS) has received a new patent from the U.S Patent and Trademark Office, entitled “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat...
View ArticleMedifocus receives two Canadian patents
Medifocus (OTCQX:MDFZF; TSX-V:MFS) has obtained two newly allowed Canadian patents covering its platform technology for the treatment of breast cancer. The titles of the patents are “Thermotherapy...
View ArticleCan-Fite gets patent in Japan for CF101
The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine...
View ArticleCan-Fite receives patent notice for sexual dysfunction drug
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The...
View ArticleRevive readies key clinical studies in gout and kidney stones
Revive Therapeutics (TSX-V:RVV; OTCQB:RVVTF) hopes to begin a pivotal Phase 2b clinical trial in mid-year with its Bucillamine drug candidate for the treatment of acute gout flares. Fabio Chianelli “We...
View ArticleLeerink starts Depomed at outperform
Leerink Partners has initiated coverage of Depomed (NASDAQ:DEPO) with an “outperform” rating and $21 price target. The stock closed at $14.62 on Wednesday. “Depomed’s Nucynta for chronic pain provides...
View ArticleOramed gets Indian patent for oral administration of proteins
Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to...
View ArticleUSPTO extends Oramed patent term
The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions...
View ArticleOramed receives patent in China
Oramed Pharmaceuticals (NASDAQ:ORMP) has received an official notification of granting patent right for the company’s patent for its invention titled, “Methods and Compositions for Oral Administrations...
View Article
More Pages to Explore .....